GLPBio

THZ531

Catalog No.: GC16420Purity:>98.00%
THZ531 は、CDK12 と CDK13 の両方の選択的共有結合阻害剤であり、IC50 はそれぞれ 158 nM と 69 nM です。

製品は研究用途にのみ使用できます。人体には使用できません。患者への販売は行っておりません。


THZ531
Cas No.: 1702809-17-3
5mgIn Stock
$70.00
1
25mgIn Stock
$245.00
1

引用文献 (Citations)

現在、この製品の引用文献はありません。以下はGlpBio製品を引用した代表的な文献です。
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

製品説明 (Description)

THZ531 is a first-in-class CDK12 and CDK13 covalent inhibitor with IC50 values of 158 nM and 69 nM, respectively [1].

 Complexes containing CDK12 and CDK13 regulate transcriptional elongation as well as processes, including mRNA splicing and 3’-end RNA processing. Loss of CDK12 and CDK13, or of their cofactor cyclin K, impedes both Pol II processivity and RNA processing [1].

THZ531 is an irreversible CDK12 and CDK13 covalent inhibitor. THZ531 potently inhibited CDK12 and CDK13 with IC50 values of 158 nM and 69 nM, whereas inhibition of CDK7 and CDK9 was more than 50-fold weaker, with IC50s of 8.5 μM and 10.5 μM, respectively. In Jurkat cells, THZ531 irreversibly reduced cell proliferation with IC50 of 50 nM. THZ531 induced apoptosis in a dose- and time-dependent way. THZ531 also reduced Pol II C-terminal domain (CTD) Ser2 phosphorylation, a mark of active transcriptional elongation, resulted in the loss of key super-enhancer-associated transcription factor genes and DNA damage response (DDR) genes expression [1].

 

Reference:

1.Zhang T, Kwiatkowski N, Olson CM, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84.

実験プロトコル (Protocol)

Kinase experiment [1]:

Binding assays

Radioactive kinase activity measurements were performed at a concentration of 0.2 μM CDK–cyclin complex. Typically, 35 μl reaction volumes of 0.2 μM active kinase were equilibrated in kinase buffer (40 mM Hepes (pH 7.6)), 34 mM NaCl, 34 mM KCl, 10 mM MgCl2, 5% glycerol, and 1× PhosSTOP. Cold ATP to a final concentration of 200 μM and 3 μCi [γ-32P]ATP and 50 μM of a substrate peptide containing five phosphorylation sites were added and the reaction mixture incubated for 30 min at 30 °C at 350 rpm in a thermomixer. Reactions were stopped by adding EDTA to a final concentration of 50 mM. Aliquots of 15 μl each were spotted onto paper squares using the Optitran BA-S85 reinforced membrane. Paper squares were washed three times for 5 min with 0.75% (v/v) phosphoric acid, with at least 5 ml washing solution per paper. Radioactivity was counted in a Beckman Scintillation Counter (Beckman Coulter) for 1 min. Compounds THZ531 was added at varying concentrations to 0.2 μM CDK–cyclin complex and incubated for varying times from 1 to 540 min at 30 °C and 350 rpm before ATP and substrate were added to the reaction mix.

Cell experiment [1]:

Cell lines

Jurkat cells

Preparation method

This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

50-1200 nM, 6 h

Applications

THZ531 treatment led to a dramatic and irreversible decrease in Jurkat cell proliferation with an IC50 of 50 nM. Treatment with escalating doses of THZ531 displayed a dose- and time-dependent increase in the number of cells exhibiting sub-G1 content. Higher doses of THZ531 led to a pronounced annexin V signal, with 30–40% annexin-V-stained cells by 72 h. THZ531 selectively reduced Ser2 phosphorylation levels without appreciable effect on CTD pSer5 or pSer7 levels. Treatment with 50 nM THZ531 resulted in the loss of expression of a small subset of genes.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Zhang T, Kwiatkowski N, Olson C M, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors[J]. Nature chemical biology, 2016.

製品資料 (Product Documents)

Purity:>98.00%Appearance:A solid

化学的性質 (Chemical Properties)

CAS番号
1702809-17-3
化学名
(R,E)-N-(4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide
SMILES
ClC1=CN=C(N[C@H]2CN(C(C3=CC=C(NC(/C=C/CN(C)C)=O)C=C3)=O)CCC2)N=C1C4=CNC5=C4C=CC=C5
分子式
C30H32ClN7O2
分子量
558.07
溶解性
≥ 55.8mg/mL in DMSO
保存条件
Store at -20°C
一般的な注意事項
製品の溶解性データに基づいて適切な溶媒を選択してください。調製後は、凍結融解の繰り返しを避けるため、ストック溶液を小分けしてください。
ストック溶液は、-80°Cで保存する場合は6か月以内、-20°Cで保存する場合は1か月以内に使用してください。
溶解性を高めるには、チューブを37°Cに温め、適切な時間超音波処理してください。
配送条件
評価用サンプルは保冷剤とともに発送します。その他の容量は室温で発送し、ご要望に応じて保冷剤を同梱します。

計算ツール (Calculators)モル濃度 / 希釈 / 分子量 / 単位変換 / in vivo製剤 / 溶解度

g/mol

Reviews

Review for THZ531

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%